# Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine?

> Research article (Nature Cardiovascular Research, 2023) · cited 13× · AI/ML

**Wikidata**: [openalex:W4384206023](https://www.wikidata.org/wiki/openalex:W4384206023)  
**Source**: https://4ort.xyz/entity/dual-sglt1-and-sglt2-inhibitor-sotagliflozin-achieves-fda-approval-landmark-or-landmine